Skip to search formSkip to main contentSkip to account menu

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

certolizumab pegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
BACKGROUND Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms… 
Review
2007
Review
2007
Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn’s… 
2006
2006
Certolizumab pegol (CDP870) for treatment of Crohn's disease.
2006
2006
CDP870 in Crohn's disease: reconsidering endpoints.
2005
2005
In Vitro Complement-Dependent Cytotoxicity and Antibody-Dependent Cellular Cytotoxicity by the Anti-TNF Agents Adalimumab, Etanercept, Infliximab, and Certolizumab Pegol (CDP870): 807
2005
2005
Effect of the Anti-TNF Agents, Adalimumab, Etanercept, Infliximab, and Certolizumab PEGOL (CDP870) on the Induction of Apoptosis in Activated Peripheral Blood Lymphocytes and Monocytes: 806
Highly Cited
2004
Highly Cited
2004
Pharmaceutical profiling in drug discovery for lead selection
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug… 
Review
2003
Review
2003
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
The introduction of infliximab, a mouse/human chimeric monoclonal antibody to tumor necrosis factor (TNF), is an important… 
2003
2003
Fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel disease
Fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel… 
2003
2003
Safety of CDP870, a pegylated humanized anti-TNF antibody fragment, in Crohn's disease
Purpose: We reported that CDP870 is effective for treatment of Crohn's disease (CD). The safety and pharmacokinetics of CDP870… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)